{"nctId":"NCT03703336","briefTitle":"Phase III Study of Liquid Formulation of ROTAVIN","startDateStruct":{"date":"2019-03-16","type":"ACTUAL"},"conditions":["Diarrhea","Diarrhea Rotavirus"],"count":825,"armGroups":[{"label":"ROTAVIN Liquid Formulation","type":"EXPERIMENTAL","interventionNames":["Biological: ROTAVIN (liquid formulation)"]},{"label":"ROTAVIN-M1 Frozen Formulation","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ROTAVIN-M1 (frozen formulation)"]}],"interventions":[{"name":"ROTAVIN (liquid formulation)","otherNames":[]},{"name":"ROTAVIN-M1 (frozen formulation)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy infants as established by medical history and clinical examination before entering the study.\n2. Age: 60-91 days (both days inclusive) at the time of enrollment.\n3. Parental/legally acceptable representative ability and willingness to provide written informed consent.\n4. Parent/legally acceptable representative who intends to remain in the area with the child during the study period.\n\nExclusion Criteria:\n\n1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment (temporary exclusion).\n2. Presence of fever on the day of enrollment (temporary exclusion).\n3. Acute disease at the time of enrollment (temporary exclusion).\n4. Concurrent participation in another clinical trial at any point throughout the entire time frame for this study.\n5. Presence of significant malnutrition (weight-for-height z-score \\< -3 SD median)\n6. Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer, or autoimmune disease) as determined by medical history and / or physical examination which would compromise the participant's health or is likely to result in nonconformance to the protocol.\n7. History of congenital abdominal disorders, intussusception, or abdominal surgery.\n8. Known or suspected impairment of immunological function based on medical history and physical examination.\n9. Household contact with an immunosuppressed individual or pregnant woman.\n10. Prior receipt of rotavirus or an intent to receive this vaccine from outside of the study center during study participation.\n11. Prior receipt of Expanded Program on Immunization (EPI) vaccination during past 7 days or plan to receive them within next 7 days.\n12. A known sensitivity or allergy to any components of the study vaccine.\n13. History of allergy to antibiotic kanamycin.\n14. Clinically detectable significant congenital or genetic defect.\n15. History of persistent diarrhea (defined as diarrhea that lasts 14 days or longer).\n16. Receipt of immunoglobulin therapy and / or blood products since birth or planned administration during the study period.\n17. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study.\n18. Any medical condition in the parent/legally acceptable representative or infant which, in the judgment of the Investigator, would interfere with or serves as a contraindication to protocol adherence.","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Days","maximumAge":"91 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies 28 Days After Second Vaccination","description":"Serum anti-rotavirus IgA antibodies were measured using a validated enzyme linked immunosorbent assay (ELISA) at the Cincinnati Children's Hospital Medical Center (CCHMC), Division of Infectious Diseases in Cincinnati, Ohio USA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.25","spread":null},{"groupId":"OG001","value":"35.04","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Reactions Within 7 Days of Vaccination","description":"Solicited post-vaccination reactogenicity included fever, diarrhea, vomiting, decreased appetite, irritability, and decreased activity level during the seven-day period after each vaccination. Parents were asked to record reactions on a post-immunization diary card.\n\nSolicited reactions were graded for severity on a scale from mild to severe based on the level of symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion 28 Days After the Second Vaccination","description":"Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if the baseline concentration was \\< 20 U/mL or a post- vaccination serum anti-rotavirus IgA antibody concentration of ≥ 4-fold baseline level if the baseline concentration was ≥ 20 U/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seropositivity at Baseline and 28 Days After the Second Vaccination","description":"Seropositivity is defined as serum IgA antibody concentration ≥ 20 U/mL","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Immediate Adverse Events (AEs)","description":"After each vaccination participants were observed at the clinic site for at least 30 minutes to check for any immediate AEs including episodes of vomiting and allergic reaction to vaccine. Immediate AEs include all reactions that occurred within 30 minutes of each vaccination.\n\nReactions were graded for severity per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, of the US National Institute of Health:\n\nGrade 1: Mild symptoms causing no or minimal interference with usual social \\& functional activities; intervention not indicated.\n\nGrade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated.\n\nGrade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated.\n\nGrade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death\n\nGrade 5: Death","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited Adverse Events","description":"An unsolicited AE was any AE that occurred after vaccination, whether or not deemed \"related\" to the product, that was not solicited, or, any solicited reaction that started after 7 days post-vaccination. Severity of unsolicited AEs was graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1.\n\nGrade 1: Mild symptoms causing no or minimal interference with usual social \\& functional activities; intervention not indicated\n\nGrade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated\n\nGrade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated\n\nGrade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death\n\nGrade 5: Death\n\nThe clinician classified the causality of each AE as related if there was reasonable possibility that the product caused the event.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events Including Intussusception","description":"All Serious adverse events (SAEs), including cases of intussusception, were recorded at all time points between first vaccination and last visit. An SAE was defined as any untoward medical occurrence that:\n\n* Resulted in death,\n* Was life threatening,\n* Required inpatient hospitalization or prolongation of existing hospitalization,\n* Resulted in persistent or significant disability / incapacity,\n* Was a congenital anomaly or a birth defect,\n* Medically important event\n\nInvestigator-confirmed cases of intussusception also qualified as an SAE in this study. Intussusception is the infolding (telescoping) of one segment of the intestine within another, usually resulting in a blockage of the intestine.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":551},"commonTop":["Pyrexia","Upper respiratory tract infection","Cough","Nasopharyngitis","Bronchitis"]}}}